AFRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AFRM is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The latest earnings beat expectations, analyst sentiment is broadly bullish with multiple Buy/Outperform ratings and higher price targets, and the stock is sitting near a constructive breakout area. I would rate it as a buy now rather than waiting for a better entry because the current setup is supportive and the user wants to act now.
AFRM is trading at 66.97, above the pivot of 65.158 and close to resistance at 68.161. MACD is slightly negative and weakening, which shows short-term momentum is not fully confirmed, but RSI_6 at 65.984 is still healthy and not overbought. Moving averages are converging, suggesting a possible trend inflection. Overall, the chart looks neutral-to-bullish with room to test 68.16 and then 70.02 if momentum continues.
Recent catalysts are favorable: Affirm reported fiscal Q3 net revenue of $1.04B, up 33.5% YoY and above expectations. EPS and net income also showed strong improvement. Analysts are raising targets and highlighting consumer spending resilience, Affirm Card momentum, and upcoming catalyst potential from company events and guidance updates.
The main negatives are the technical MACD weakness, the recent revenue decline in the financial snapshot for 2026/Q3, and elevated valuation sensitivity typical for a growth fintech stock. There are also no strong insider, hedge fund, or congress buying signals to reinforce conviction, and no recent political/influential figure trading activity was reported.
Latest quarter shown: fiscal Q3 2026. Revenue dropped to 704.3M, down 10.07% YoY, while net income rose to 102.9M and EPS climbed to 0.30, both sharply higher year over year. Gross margin eased to 90.35%, down 2.51% YoY. Separately, the earnings news for QMAR 2026 showed a revenue beat at $1.04B, up 33.5% YoY, which is the more important recent operating update and supports a growth-positive view.
Wall Street is mostly positive on AFRM. Truist raised its target to $75 and kept Buy; BMO initiated Outperform with $75; Cantor raised to $80 with Overweight; Evercore stayed Outperform with $90; Morgan Stanley named it a Top Pick with $76; Citi keeps Buy with $100 and a 90-day upside catalyst watch; TD Cowen and BofA also remain bullish. The pros view is that growth is improving, catalysts are building, and recent valuation resets create upside. The con side is that some firms have trimmed targets due to macro and consumer-credit concerns, so sentiment is positive but not universally aggressive.
